Alidornase alfa - Protalix Biotherapeutics

Drug Profile

Alidornase alfa - Protalix Biotherapeutics

Alternative Names: AIR DNAse™; PRX 110

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protalix BioTherapeutics
  • Class Antibacterials; Antifibrotics; Pentanoic acids; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 23 May 2017 Protalix Biotherapeutics completes a phase IIa trial in Cystic fibrosis (In adolescents, In adults, Treatment -experienced) in Israel (Inhalation) (NCT02722122)
  • 12 Apr 2017 Updated efficacy, antimicrobial and pharmacokinetics data from a phase II trial in Cystic fibrosis released by Protalix BioTherapeutics
  • 08 Feb 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top